Senior Partners

Milipore Sigma

Ajinomoto BioPharma Services

Senior Partner

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.  Ajinomoto Bio-Pharma Services is establishing itself as a premier, US-based provider for high-containment bioconjugate manufacturing, as well as fill and finish services for both Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC).

NJBIO logo new

NJ Bio, Inc. 

Senior Partner

NJ Bio, Inc. is a US-based CRO that provides high-quality integrated chemistry and biology services for bioconjugations and ADCs to biotech and pharmaceutical companies – from start-up to big pharma. Main service areas include linker-payload synthesis for ADCs, bioconjugations and antibody-drug conjugates as well as bioassay and bioanalytical services. With our expertise and experience in the ADC field, we strive to create value for our clients by advancing their programs. Please contact info@njbio.comor visit our website.




Senior Partner

Synaffix is a biotech company with a proprietary, clinical-stage ADC platform technology enabling ADCs with improved therapeutic index compared to all 3 major clinical-stage ADC technologies. 

Our consolidated technology platform includes GlycoConnect™ antibody conjugation, HydraSpace™ polar spacer and toxSYN™ linker-payload technologies, which can be accessed together by any company with an antibody, to develop their own proprietary, best-in-class ADC.

Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 9 partners and well over $3Bn in total potential value from our out-licensing deals.



Senior Partner

Tubulis generates uniquely matched antibody-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. 

Tubulis has developed a dual platform approach for the discovery and development of a new generation of versatile and customizable ADCs. 

Combining our unique payload platform Tubutecan with our high-DAR linker technology P5, results in superior DAR8 ADC perfectly matched to target solid malignancies.

XDC with WuXi Bio_4C

Wuxi Biologics

Senior Partner

WuXi XDC, a WuXi Biologics subsidiary, is a joint venture between WuXi Biologics and the WuXi AppTec subsidiary, WuXi STA, providing end-to-end contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs).  Our open access bioconjugation platform accelerates and transforms the discovery, development, and manufacturing of bioconjugates, ‘Linking innovation to health’, enabling our global healthcare partners and benefiting patients worldwide, with the most comprehensive capabilities and technologies in the biologics industry.




AbbVie Contract Manufacturing





AbTis’ proprietary next-generation ADC linker technology enables specific number of payloads to bind to specific sites without antibody engineering.  ADC linker is one of the major factors to influence efficacy, safety and CMC of ADC.  AbTis’ technology employs a linker binding to specific site of antibody for payload conjugation without antibody engineering.  It can bind a certain number of payloads to a specific site (DARs 2, 4, 8 are made).  Its technology utilizes proximity effects to bind payloads to the lysine on Fc site of antibody.  AbTis has its ADC pipelines, such as Claudin18.2 and Her2 ADCs and antibody-radioisotope conjugates.





Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US.  Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients.  Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.




Ardena is a fully integrated pharmaceutical CDMO with a core focus on bringing molecules to the clinics. We offer drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with our customers to compile their regulatory dossier to fast-track their product towards compliance.

Ardena is uniquely positioned to offer quantitative bioanalysis from discovery research through GLP compliant preclinical assessments to late-stage clinical development. As such, we have supported numerous programs to assess the PK and immunogenicity of various ADCs using ligand binding assays as well as (hybrid) LC-MS/MS analysis.


AsymchemLogo-01 (002)



Asymchem is a global integrated CDMO providing drug R&D and manufacturing for leading pharmaceutical and biotech companies. Our mission is to drive smarter, greener and more cost-effective manufacturing to support clinical research and commercialization. Asymchem currently operates eight manufacturing facilities offering solutions ranging from early clinical stage to commercial stage, including ADCs. In addition to the small molecule HPAPI and peptide water head production, Asymchem can support production of the linker. We are also growing and developing our (monoclonal) antibody and conjugation capabilities, organically.






Beacon 2017 (002)

Beacon Targeted Therapies


We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world. We work in targeted therapies such as targeted protein degradation to provide accurate, in-depth, and real-time information in the rapidly evolving landscape of drug development.  

Find out how we can accelerate your drug development program by visiting our website.


biocytogen logo

Biocytogen Pharmaceuticals


Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.


BI_PMS288 300 ppi (002)

Boehringer Ingelheim


Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at




BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic  drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.





Catalent Biologics logo

Catalent Biologics


Company logo_Chiome Bioscience_220805 (002)

Chiome Bioscience Inc.


CytomX Logo_RGB (002)




Glyco T Therapeutics


GlycoT Therapeutics is a platform technology-based biotech company specializing in glycoengineering of antibodies and site-specific antibody-drug conjugates. Our innovative and proprietary chemoenzymatic platform technology allows site-specific glycoengineering to produce various homogeneous antibody glycoforms, structurally well-defined and antibody-drug conjugates (ADCs) as therapeutic and diagnostic products. Its leading-edge and proprietary technology permits glycoengineering of antibodies to provide Fc glyco-site-specific ADCs in just one or two enzymatic steps, with improved quality attributes and therapeutic index. GlycoT has successfully sublicensed its technology to pharmaceutical and biotech companies to develop therapeutic (including ADC) or diagnosis product, including Daiichi Sankyo, Genovis, and other companies.




Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.





IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies. The company has developed a state of the art linker technology comprising of a novel self-immolative group based on OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker is designed to release phenolic payloads through intramolecular cyclization, mediated by ortho-hydroxyl group temporarily blocked by a triggering group. The technology has been extended to non-phenolics by introducing a phenolic spacer. The linker, with or without phenolic spacer, has been applied to full ADCs, which showed excellent dose dependent efficacy both in vitro and in vivo.

johnson and johnson

Johnson & Johnson


At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at

무제-1 사본

LegoChem Biosciences


LegoChem Biosiences is a clinical stage biotech with expertise in medicinal chemistry. It has several antibiotic programs for infectious disease with urgent needs and drugs in oncology and anti-fibrosis. It has extended its expertise to ADC and developed next-generation site-specific ADC platform with novel linker that improves stability of ADCs in blood circulation, effectively prevents premature drug release, efficiently facilitates liberation of the drug at targeted tumor cells and ultimately shows significant improved therapeutic index.




Levena Biopharma is a global ADC CRO/CDMO dedicated to advancing Antibody Drug Conjugate programs from discovery to the clinic and beyond. We have facilities in San Diego (R&D)-- Suzhou (CMC and cGMP). Levena provides synthetic and conjugation services ranging for mgs to 100s’ grams scale. As well as complete ADC characterization using advanced analytical tools. We have collaborated on dozens of IND projects with our partners.  Our proprietary and non-proprietary ADC solutions include Linkers, Payloads, of mechanistically defined ADCs with exacting, reproducible performance for safety, efficacy, clinical success with a track record to prove it.




LiVeritas Biosciences empowers biopharmaceutical companies to meet accelerated biologics drug development timelines via rapid and strategic "phase appropriate" implementation of machine learning-powered mass spectrometry analysis. LiVeritas offers state-of-the-art LC-MS instrumentation and mass spec solutions in proteomics, metabolomics and other novel biomolecules. LiVeritas created “Mass Spec as a Service” (MSaaS), a suite of automated workflow solutions and software tools enabling drug developers to integrate mass spec data in pre-clinical and early clinical testing for new therapeutics.




Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact or visit

Mersana logo - CMYK - vector (002)

Mersana Therapeutics


Mersana is a clinical-stage biopharmaceutical company using its proprietary ADC platforms to develop novel ADCs designed for optimal efficacy and safety to improve the lives of people fighting cancer. Mersana’s lead candidate upifitamab rilsodotin (UpRi) is a NaPi2b-targeting ADC being studied in UPLIFT, a single-arm registrational trial in platinum resistant ovarian cancer, UP-NEXT in recurrent platinum sensitive ovarian cancer, and UPGRADE in combination with carboplatin in platinum sensitive ovarian cancer. The company’s earlier stage candidates include XMT-1660, a B7-H4 directed Dolasynthen ADC, and XMT-2056, a STING agonist ADC, which are being investigated for a range of solid tumors.




MilliporeSigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life saving therapies. We have the largest offering of products for formulations, actives and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts and stabilizers and from chromatography to TFF equipment, including single-use templates.








NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbates 20 and 80. Our cutting edge products include single molecule PEG linkers for ADCs “PIREBRIGHT Series” and SS-lipids for nucleic acid and gene delivery “COATSOME SS Series”.



Novasep & PharmaZell Group


Novasep & PharmaZell Group has been a leading contract service provider in the ADC arena for more than 10 years and provides unique services for the development, clinical supply and commercial manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody.

Our commitment to ADCs is underlined by the recent €11M investment in a stand-alone bioconjugation unit at our Le Mans site in France. The site has more than 30 years of experience in synthesis & purification of cytotoxics using industrial chromatography.


Copy of Induced Proximity Company banner (2)

Olon S.p.A.


Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and Generics.

It provides an integrated package of chemical synthesis and biological processing services which clients can use to manage their drug manufacturing projects fully compliant with regulations.

We rely on a global network of 11 manufacturing site and 7 R&D departments across the globe, on several decades of experience in supporting pharmaceutical.





OmniAb provides the industry's only offering with three transgenic animal species, strategically built to optimally harness the unparalleled power of Biological Intelligence. OmniAb's offerings of OmniRat®, OmniMouse®, OmniChicken®, OmniFlic®, OmniClic®  and OmniTaur™ also broadened to include antigen design and other technologies that supplement the animal offerings. As a leader in transgenic animal technology, we are committed to providing technologies that enable and enhance the discovery of therapeutic antibodies.


Piramal Pharma Solutions logo_RGB (002)

Piramal Pharma Solutions


Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.           

For more information please visit: | Twitter  | LinkedIn





Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.



Copy of Induced Proximity Company banner (1)

SafeBridge Consultants, Inc


SafeBridge Consultants, Inc. is the premier resource for high-level safety, health and environmental support to the pharmaceutical and biotechnology industry.  Comprised of industry leaders in toxicology, analytical chemistry and industrial hygiene. SafeBridge has developed the “brand name” in the pharmaceutical industry as a leader in the field of advanced worker protection programs for potent drug handling and risk assessment for product protection. SafeBridge has locations in Mountain View, California, New York City and London, England.






The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.

Sterling Full Colour Logo

Sterling Pharma Solutions


Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In April 2021 Sterling acquired ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation. Together, as Sterling Pharma Solutions, the teams have developed an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise. 

Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.

Exhibitor Partners




Absci's AI-powered biologics creation platform has been specifically designed to allow site-specific incorporation of non-standard amino acids into what we call Bionic Proteins(TM). This enables generation of ADCs with optimized DARs, better product homogeneity, and readily scalable manufacturing leading to lower costs and higher yields.

For more information visit


Amador logo-EN

Amador Bioscience


Amador Bioscience is a global leading translational & clinical research CRO, and has established sites in China, the US, and Europe.​

As a leading partner for successful innovative drug R&D, Amador Bioscience drives the development of new drugs with clinical pharmacology, providing the complete chain of clinical development services in line with international standards. The services include the development and approval process from pre-clinical to NDA/BLA. We scientifically “choose dose, choose target, choose patient,” and utilize global implementation of quality standards to enhance the success rate of new drugs.



Aptamer Group


Aptamer Group is the developer of custom affinity tools for the life science industry through its proprietary Optimer® platform. 

Optimer binders are nucleic acid-based affinity ligands that can be used as an antibody alternative to offer novel solutions and improvements to current processes across the therapeutic, diagnostic, bioprocessing and research sectors. The Optimer platform consists of three parallel processes optimized for target type to enable scientists with the best affinity ligand for small molecules, proteins or cell targets. 

Offering rapid development in just weeks, full platform compatibility and tuneable binding kinetics to ensure desired end-use performance, Optimer binders are enabling new insights and new molecules to progress life science for better healthcare for all.


Benchmark Products

Benchmark Products




Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis for ADCs, and Flexibody™ bispecific platforms. Biosion has operations in the US, Australia, and China.





We get it.  You are committed to helping patients with lifesaving therapeutics. ADCs provide significant value in meeting this goal. ProteinSimple is the instrument division in Bio-Techne, and we share your commitment.  We are humbled that our iCE technology is being used in the vast majority of commercial ADC therapeutics.  Maurice provides icIEF and CE-SDS analysis and is the gold standard, based on ease of use and on easily developing platform assays.  Come see us.


BPS logo with white circle--transparent

BPS Bioscience


BPS Bioscience’s purpose is to advance new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, coronavirus, CRISPR, cell signaling, and others, providing 4000+ high quality recombinant cell lines, lentiviruses, proteins and all aspects of biochemical and cell-based assay development. As a primary manufacturer, we can supply products in large-scale bulk quantities, as well as contract and custom manufacturing. Our biochemical and cell-based screening services are also available to accelerate your research.


BroadPharm logo 04262022-01 (002)



BroadPharm is a leading customer-focused biotech company in San Diego. We are dedicated to manufacturing and supplying high purity PEG reagents, ADC linkers, & Bio-labeling tools to our clients worldwide. Our ADC linker products include cleavable & non-cleavable ADC linkers, site specific ADC linkers, PEGylated and branched ADC linkers.

BroadPharm also offers IP-protected custom synthesis & conjugation for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client’s needs & offer advice for the best use of our new products.



Cfm Oskar Tropitzsch GmbH


A German/Bavarian based company that offers a unique selection of payloads for ADCs. We provide state of the art molecules as well as contract manufactured payloads – derived from fermentation, soil, algae or chemically synthesised. Non GMP for early R&D up to cGMP for APIs made in Europe. Our reliability, flexibility, independence and reputation are our key success factors.


Champions_2021 (002)

Champions Oncology


Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit


Creative Biolabs (002)

Creative Biolabs


Proficient in antibody biochemistry and engineering, Creative Biolabs has taken the lead in targeted immunotherapy and ADC development and established a comprehensive one-stop shop for ADC research and evaluation, covering antigen selection, antibody production and optimization, payload-linker synthesis, ADC conjugation, and extensive ADC characterization and pre-clinical evaluation. In addition, Creative Biolabs maintains a stock of custom-prepared products for quick deployment and concept validation regarding ADC R&D, containing an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs.


detaibio logo



Nanjing Detai Bioengineering Co., Ltd. (“DetaiBio”), established in 2013, is a CRO vendor focusing on antibody discovery and functional protein research files. DetaiBio is aiming to provide high-quality and economic offer service to speed up life science for our clients in different fields, such as antibody drug discovery, in-vitro diagnosis, and academic research.

Currently, DetaiBio has established different platforms including FACS sorting, plasma cell sorting, hybridoma sequencing, single-cell sequencing, structure analysis, High-throughput recombinant protein/recombinant antibody, stable cell line development, etc, to support service upgrading, internal R&D, and high QC standard.

The main services offered by DetaiBio:

----SingleB® for antibody/VHH discovery service

---- High-throughput recombinant antibody expression service (1-week delivery),

----Hybridoma sequencing service

----Customize protein expression service (E.coli, Insect, Mammalian) 

Detaibio will continue more efforts to accelerate the research in life science (biotech and biopharma industry, IVD and academic field), to achieve a win-win for both DetaiBio and our partners.








Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our efforts have resulted in four approved products and we have partnered with leading pharmaceutical companies to make these available to patients worldwide. We are committed to prudently reinvesting in our business to maximize the potential of our pipeline, through both targeted business development and internal drug discovery – all to help cancer patients recover stronger and live longer.

Copy of Induced Proximity Company banner (3)

Goodwin Biotechnology


Goodwin Biotechnology’s mission is to eliminate the manufacturing risk for companies developing complex biologic therapeutics by being the pre-eminent provider of high-quality, cost-effective, flexible and timely cGMP compliant manufacturing solutions, from pre-clinical development through commercial product supply. By integrating our services in one location, Goodwin provides a Single Source Solution™ to anticipate and overcome the challenges you face with your biopharmaceutical candidate, whether it be complex proteins such as monoclonal antibodies or a sophisticated Antibody Drug Conjugate (ADC).


Imagen Logo-New-Rect-Smoothed-1 (002)

Imagen Therapeutics


Imagen Therapeutics is a leading provider of end-to-end in vitro pharmacology services utilizing primary patient tumor samples and have applications for both patient diagnostics and oncology drug development.

Our unique technology harnesses the power of high-content imaging to visualize treatment outcomes with the largest collection of patient-derived cell (PDC) models predictive of clinical response. For ADC applications, we can assess cell surface binding, internalization, degradation and cytotoxic readouts.

Imagen’s technology platform offers direct patient benefit with our predictRin vitro diagnostic tool while accelerating and de-risking drug development with predictTx drug screening offering for biopharma.


mabplex logo



MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.

Logo_Shanghai Haoyuan MedChemExpress_PNG-01



ChemExpress is a CDMO supplier of small molecule APIs and intermediates, offering custom synthesis (FFS, FTE), process development, CMC management and IND filing. Our patent technologies (CN06380508, 2015; CN107805274A, 2017; CN111470998, 2020, etc.) enables us to make MC-VC-PABC-MMAE and Exatecan at low cost. A variety of payloads, linkers, toxins and intermediates are available in large scale (g to 100+ g), including auristantins (MMAE, MMAF, MMAD), doxorubicin, tululysins, campathecins (Exatecan, SN38), maytansinoids (DM1, DM2, DM4), ascidiantin (Trabectedin) and halichondrin (Eribulin). We promise quality CDMO services tailored to your budget and timeline.



Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.

logo_munit (002)



MUNIT is a consultancy company, operating in the field of MICRONIZATION of Active Pharmaceutical Ingredients (APIs), High Potent APIs, Cytotoxic and Cytostatic compounds, Inhalation products, Steroids, R&D compounds and Generics. In MUNIT we have combined the technical and commercial expertise of its affiliates Jetpharma SA (Switzerland) and Microchem Srl (Italy) making the best out of 40 years of leadership in the micronization sector.
The triangular company structure  with its back-up potential, its technology transfer and the resulting flexibility is one of our unique features in the market and an important part of customers Business continuity plan.
With MUNITs lean organisation, its welcoming and customer orientated attitude, we are able to guarantee best service, high efficiency and punctuality to our customers worldwide.





Nicoya is a Canadian biotechnology company specializing in innovative biosensor technology for the biopharmaceutical and academic sectors. In their mission to improve human life, Nicoya provides scientists with integrated and intuitive SPR solutions that accelerate discovery and characterization of biologics. Nicoya's benchtop instruments are now enabling hundreds of scientists in over 50 countries with best-in-class data for their life-changing research. Learn more at



PPD, part of Thermo Fisher Scientific


PPD, part of Thermo Fisher Scientific, provides laboratory services that combine high-quality scientific expertise with industry-leading technologies supported by a commitment to exceptional quality to deliver integrated analytical services to the pharmaceutical landscape. Our customers benefit from comprehensive laboratory services backed by our more than 35 years of experience as a clinical research organization. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, we serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, we apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.



Precision Antibiody


Quanta BioDesign


Quanta BioDesign's dPEG® platform is founded upon discrete MW PEGs, which enable assembly of unique structures with single-molecule precision and without the liabilities associated with hydrophobic carbon-based linkers. Broadly speaking, ADCs combine an antibody's antigen-targeting properties with a payload's cell-killing properties. The dPEG® product line facilitates linker architectures that enhance a conjugate's tumor-targeting properties by altering its physicochemistry, pharmacokinetics, and biodistribution (See Chemical Linkers in Antibody Drug Conjugates, Royal Society of Chemistry, 2021). Tailoring these properties, through the optimal incorporation of dPEG® components, to shift in vivo delivery from off-target to tumor-targeted pathways has the potential to improve therapeutic margins.


ReachBio Research Labs (PRNewsfoto/ReachBio Research Labs)



ReachBio provides primary cell biology contract research services to the drug development and life science research community. With a special focus on hematopoietic (blood and bone marrow) primary cell systems, our platform is broad and includes predictive and investigative toxicology, immunology, efficacy testing, cell bank development, biomarker selection, flow cytometry/cell sorting, and assay development and. ReachBio has developed two distinct assay platforms to assess cytotoxicity caused by ADCs.



Sanyou Biopharmaceuticals 


Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 250+ employees, R&D laboratories of 20000 m2 and 300+ clients and partners all around the world.


Symbiosis Logo



Symbiosis Pharmaceutical Services is a contract development and manufacturing organisation (CDMO) specialising in the GMP manufacture and sterile fill/finish of vials for clinical trials and commercial supply.

Manufacturing from a purpose-built FDA inspected and MHRA-licensed facility, the CDMO can handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs.

Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product sterile manufacturing.


veranova-logo-tm_rgb (002)



Veranova, formerly Johnson Matthey Health, is a global leader in the development and manufacturing of APIs for pharma and biotech customers.

We’ve been working with pharma innovators for over 50 years, providing a range of specialised services for developing our customers’ complex and niche molecules. Our highly skilled process chemists and analytical scientists possess a wealth of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody drug conjugates (ADCs), polymer drug conjugates and other drug delivery applications.

Our leading services are supported by our network of exceptional facilities spanning Europe, North America and Asia.




VERAXA is an early-stage biotechnology company with game changing antibody discovery and conjugation technology yielding ADCs at scale. Our proprietary high throughput droplet-based microfluidic platform can screen entire immune repertoires with millions of antibody secreting cells for antibody binding, functionality, and internalization on a single-cell level. Our unique ADC technology utilizes genetic code expansion and bioorthogonal click chemistry to precisely and efficiently conjugate payloads at freely selectable antibody sites. Our technology generates ADCs with highly narrow DARs and improved PK/PD. We offer multiple collaboration and partnering options.